Fungal Infections

Olorofim Receives Breakthrough Therapy Designation for Invasive Fungal Infections

The Food and Drug Administration has granted Breakthrough Therapy designation to olorofim (formerly F901318; F2G) for the treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species. Olorofim is part of a new…

Novel Antifungal Gains Fast Track Designation for Seven Indications

The Food and Drug Administration (FDA) has granted Fast Track designations to both the oral and intravenous formulations of fosmanogepix (APX001; Amplyx Pharmaceuticals) for 7 antifungal indications, including treatment of: invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis and coccidioidomycosis. Fosmanogepix is a broad spectrum antifungal with a novel mechanism of action that has demonstrated…

New Drug Product: Tolsura

This slideshow reviews drug information for Tolsura. This slideshow reviews drug information for Tolsura.